Inicio・Lista de Acciones・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Cerrado

15.7 -2.91

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

15.51

Máximo

15.87

Métricas clave
By Trading Economics
Ingresos	-1.4M -14M
BPA	-0.15
Empleados	37
EBITDA	312K -12M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+101.66% upside

Dividendos
By Acuity
Próximas Ganancias	6 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-71M 1.3B
Apertura anterior	18.61
Cierre anterior	15.7

Corvus Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 jul 2026, 23:56 UTC

Wynn Resorts shares are trading lower in after-market hours. Broader market volatility and rising treasury yields may be impacting sentiment for casino stocks.

10 jul 2026, 23:56 UTC

Vanguard Mortgage-Backed Securities ETF remains roughly flat in after-market trading, positioned near the lower end of its one-month trading range.

10 jul 2026, 23:56 UTC

Social Media

Baidu Inc. shares are lower in after-market trading amid regulatory scrutiny over AI technologies and security concerns regarding U.S.-China relations.

10 jul 2026, 23:56 UTC

No specific news was identified for Intuit Inc. during after-market hours, with trading activity remaining relatively flat since Friday's close.

10 jul 2026, 23:56 UTC

ETF Constituents

Health Care Select Sector SPDR Fund trades roughly flat after-market hours, impacted by declines in holdings like Thermo Fisher Scientific and Eli Lilly.

10 jul 2026, 23:51 UTC

Mixed Asia equity markets as Japan's Nikkei rises on AI rally while China's A50 falls; U.S. futures flat ahead of earnings season amid geopolitical tensions and inflation concerns.

10 jul 2026, 23:51 UTC

U.S. equity indices remain flat as investors weigh upcoming earnings and inflation reports amid geopolitical tensions and mixed global market performance.

10 jul 2026, 23:51 UTC

Global equity markets remain flat as investors weigh mixed economic signals and geopolitical tensions ahead of earnings season.

10 jul 2026, 23:51 UTC

Europe's equity markets remain flat as mixed economic data and geopolitical tensions weigh, while the Bank of England hints at potential interest rate hikes amid rising inflation concerns.

10 jul 2026, 23:51 UTC

Canada's Housing Starts Data for June 2026 Set to Release with Analysts Forecasting 260K Units Amid Government Initiatives to Tackle Housing Crisis.

10 jul 2026, 23:51 UTC

NetEase Inc. shares are higher in after-market trading, gaining since Friday's close and remaining near the upper end of their one-month trading range.

10 jul 2026, 23:51 UTC

ETF Constituents

Social Media

Vanguard Value ETF trades lower in after-market hours as holdings decline. Despite this, value stocks reached a record weekly high.

10 jul 2026, 23:51 UTC

ETF Constituents

VanEck Gold Miners ETF advances in after-market trading, supported by positive returns from GOLD and AGI, despite flat global equity indices.

10 jul 2026, 23:51 UTC

Skyworks Solutions Inc shares are higher in after-market trading, reflecting a steady increase since Friday's close without any specific news driving the movement.

10 jul 2026, 23:46 UTC

Social Media

ETF Constituents

SPDR S&P 500 ETF Trust shows stability in after-market trading, gaining since Friday's close and nearing all-time highs amid bullish market sentiment.

10 jul 2026, 23:46 UTC

Biomarin Pharmaceutical shares are lower in after-market trading, retracing from earlier highs. No specific news was identified to explain the movement.

10 jul 2026, 23:46 UTC

Macro News

ETF Constituents

After-market trading for the Communication Services Select Sector SPDR Fund shows strength, supported by gains in Meta Platforms and other key holdings.

10 jul 2026, 23:46 UTC

ETF Constituents

Global X Copper Miners ETF declines after-market, remaining near the lower end of its one-month trading range amid ongoing geopolitical tensions regarding Iran.

10 jul 2026, 23:46 UTC

ETF Constituents

Social Media

Invesco QQQ Trust Series I gains in after-market hours, supported by bullish social media sentiment and strong performances from top contributors like Amazon and Applied Materials.

10 jul 2026, 23:41 UTC

ETF Constituents

Financial Select Sector SPDR Fund declines in after-market trading, impacted by negative returns from Mastercard, American Express, and others despite broader market gains.

10 jul 2026, 23:41 UTC

US Producer Price Inflation Expected to Rise 0.2% in July Amid Cautious Economic Sentiment and Geopolitical Tensions

10 jul 2026, 23:41 UTC

U.S. Core Producer Prices Expected to Rise 0.4% in July Amid Ongoing Inflation Concerns and Geopolitical Tensions

10 jul 2026, 23:41 UTC

Mixed market sentiment prevails as investors await the NY Empire State Manufacturing Index and key inflation reports amid geopolitical tensions.

10 jul 2026, 23:41 UTC

Macro News

Correlated Moves

Bitcoin is trading higher, supported by market sentiment and Circle Internet Group's approval for a national trust bank for digital asset custody services.

10 jul 2026, 23:36 UTC

ETF Constituents

The iShares Core MSCI EAFE ETF is trading lower in after-market hours, with declines from top holdings like Novo Nordisk and SAP.

10 jul 2026, 23:36 UTC

Invesco DB Agriculture Fund trades roughly flat in after-market hours. This stability aligns with mixed signals from recent economic data and geopolitical developments.

10 jul 2026, 23:31 UTC

Brazil's Retail Sales MoM Release on July 16, 2026: Market Cautious Amid Mixed Reports and Rising Inflation Concerns.

10 jul 2026, 23:26 UTC

Charter Communications Inc shares are slightly higher in after-market hours, continuing an upward trend since Friday's close amid broader geopolitical concerns.

10 jul 2026, 23:26 UTC

Cintas Corp shares were roughly flat during after-market hours, reflecting routine trading activity. The asset remains near the upper end of its one-month range.

10 jul 2026, 23:26 UTC

ETF Constituents

The iShares MSCI Brazil ETF is trading higher in after-market hours, supported by PBR.A, despite a slight decline in PBR. Global indices remain flat.

Comparación entre iguales

Cambio de precio

Corvus Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

101.66% repunte

Estimación a 12 Meses

Media 31.6 USD 101.66%

Máximo 40 USD

Mínimo 27 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Corvus Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Corvus Pharmaceuticals Inc Dist en los últimos 3 meses.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.